Billionaire Ken Fisher’s Top 10 High Growth Stock Picks

2. Eli Lilly and Company (NYSE:LLY)

Net revenue growth in the past 12 months: 27.41%

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical powerhouse renowned for pioneering advancements in therapeutic areas such as diabetes, oncology, neuroscience, and immunology.

Eli Lilly and Company (NYSE:LLY) reported robust financial performance in Q3 2024, with revenue surging 20% year-over-year to $11.44 billion, driven by the strong performance of its GLP-1 drugs, Mounjaro and Zepbound. These medications have significantly bolstered the company’s foothold in the weight-loss drug market, contributing substantially to revenue growth.

The company has also made strides in expanding its portfolio and market reach. Eli Lilly and Company (NYSE:LLY) is in advanced negotiations to acquire cancer-focused biotech Scorpion Therapeutics for up to $2.5 billion. This move aims to diversify its pipeline with promising oncology treatments, signaling a strategic focus on strengthening its presence in the cancer treatment space.

Additionally, Eli Lilly and Company (NYSE:LLY)’s Zepbound recently received FDA approval for treating obstructive sleep apnea in obese patients. This approval allows Medicare Part D plans to cover the drug for this specific use, potentially generating over 3.7 million new prescriptions annually. This regulatory milestone could significantly increase the drug’s market potential.

Eli Lilly and Company (NYSE:LLY) is also bolstering its manufacturing capacity with a $3 billion investment in a newly acquired facility in Kenosha County, Wisconsin, to support its growing pipeline and meet increased demand for its innovative therapies.